Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(5):622–627. doi: 10.1038/bjc.1997.435

Plasminogen activator inhibitor type 2 in breast cancer.

C Duggan 1, S Kennedy 1, M D Kramer 1, C Barnes 1, P Elvin 1, E McDermott 1, N O'Higgins 1, M J Duffy 1
PMCID: PMC2228003  PMID: 9303361

Abstract

The serine protease urokinase plasminogen activator (uPA) is causally involved in cancer invasion and metastasis. Activity of this protease in vivo is controlled principally by two inhibitors, one of which is plasminogen activator inhibitor type 2 (PAI-2). In this study, we show that PAI-2 levels were significantly higher in primary breast carcinomas (n = 152) than benign breast tumours (n = 18). In the primary cancers, PAI-2 levels correlated weakly but significantly with those of uPA and PAI-1, but not with tissue type plasminogen activator (tPA) or uPA receptor (uPAR) levels. Using Northern blotting, mRNA for PAI-2 was found in 28.6% of 49 primary breast cancers. In contrast to findings at the protein level, PAI-2 mRNA levels failed to correlate with those for uPA or PAI-1. After immunocytochemistry with primary cancers, PAI-2 was detected predominantly in the malignant cells of primary carcinomas but was also present in stromal cells. Using the median value as a cut-off point, PAI-2 showed no significant relationship with either disease-free interval or overall survival. However, using an optimum cut-off value, patients with low levels of PAI-2 had a worse outcome than those with a high level. We conclude that, unlike PAI-1, high levels of PAI-2 may be a favourable prognostic marker in breast cancer.

Full text

PDF
622

Images in this article

625Figure 4
on p.625
625Figure 3
on p.625

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Georg B., Lund L. R., Riccio A., Stacey S. N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990 Jan 2;68(1):1–19. doi: 10.1016/0303-7207(90)90164-4. [DOI] [PubMed] [Google Scholar]
  2. Baker M. S., Bleakley P., Woodrow G. C., Doe W. F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res. 1990 Aug 1;50(15):4676–4684. [PubMed] [Google Scholar]
  3. Bianchi E., Cohen R. L., Dai A., Thor A. T., Shuman M. A., Smith H. S. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995 Mar 3;60(5):597–603. doi: 10.1002/ijc.2910600505. [DOI] [PubMed] [Google Scholar]
  4. Bouchet C., Spyratos F., Martin P. M., Hacène K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994 Feb;69(2):398–405. doi: 10.1038/bjc.1994.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cajot J. F., Bamat J., Bergonzelli G. E., Kruithof E. K., Medcalf R. L., Testuz J., Sordat B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6939–6943. doi: 10.1073/pnas.87.18.6939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  7. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988 Mar 1;48(5):1348–1349. [PubMed] [Google Scholar]
  8. Duffy M. J., O'Siorain L., Waldron B., Smith C. Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies. Clin Chem. 1986 Oct;32(10):1972–1974. [PubMed] [Google Scholar]
  9. Duffy M. J. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996 Apr;2(4):613–618. [PubMed] [Google Scholar]
  10. Duggan C., Maguire T., McDermott E., O'Higgins N., Fennelly J. J., Duffy M. J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer. 1995 May 29;61(5):597–600. doi: 10.1002/ijc.2910610502. [DOI] [PubMed] [Google Scholar]
  11. Foekens J. A., Buessecker F., Peters H. A., Krainick U., van Putten W. L., Look M. P., Klijn J. G., Kramer M. D. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 1995 Apr 1;55(7):1423–1427. [PubMed] [Google Scholar]
  12. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Kramer M. D., Jänicke F., Klijn J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994 Aug;12(8):1648–1658. doi: 10.1200/JCO.1994.12.8.1648. [DOI] [PubMed] [Google Scholar]
  13. Foucré D., Bouchet C., Hacène K., Pourreau-Schneider N., Gentile A., Martin P. M., Desplaces A., Oglobine J. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer. 1991 Nov;64(5):926–932. doi: 10.1038/bjc.1991.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  15. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  16. Mueller B. M., Yu Y. B., Laug W. E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):205–209. doi: 10.1073/pnas.92.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pyke C., Kristensen P., Ralfkiaer E., Eriksen J., Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991 Aug 1;51(15):4067–4071. [PubMed] [Google Scholar]
  18. Reilly D., Christensen L., Duch M., Nolan N., Duffy M. J., Andreasen P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 1992 Jan 21;50(2):208–214. doi: 10.1002/ijc.2910500209. [DOI] [PubMed] [Google Scholar]
  19. Soff G. A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H. C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995 Dec;96(6):2593–2600. doi: 10.1172/JCI118323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sumiyoshi K., Serizawa K., Urano T., Takada Y., Takada A., Baba S. Plasminogen activator system in human breast cancer. Int J Cancer. 1992 Feb 1;50(3):345–348. doi: 10.1002/ijc.2910500303. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES